Results 51 to 60 of about 2,524 (195)

Real-world effectiveness of nirsevimab against respiratory syncytial virus in pediatric practice: the Piemonitorab study

Italian Journal of Pediatrics
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in pediatric populations, resulting in a substantial burden of disease.
Elisa Funiciello, Alessia Spadavecchia, Celeste Cagnazzo, Lorenza Ferrara, Bartolomeo Griglio, Antonino Sottile, Paola Berchialla, Franca Fagioli, on behalf of the Piemonitorab Study Group   +8 more
doaj   +1 more source

Cross‐Neutralizing and Broadly Neutralizing Human Antibodies Against Nonenveloped Viruses

European Journal of Immunology, Volume 56, Issue 10, October 2026.
In this review article, Marchand et al. compare cross ‐ and broadly ‐neutralizing human antibodies against non ‐ enveloped viruses from several major families, discussing their structural characteristics, neutralization mechanisms and relevance for the development of antiviral vaccines and therapeutics.
Sarah Marchand, Samy Taouli, Dorian McIlroy   +2 more
wiley   +1 more source

Impact du nirsevimab sur les infections pédiatriques au VRS en Belgique en 2024-2025 : une analyse des données de surveillance sentinelle de routine de Sciensano

Nous estimons que 35 à 45 % des hospitalisations ont été évitées grâce à l’introduction du nirsevimab. Nous estimons que l’introduction du nirsevimab a permis de diminuer de 35 à 45 % les hospitalisations liées à une infection au VRS chez les enfants de ...
T. Braeye, A. Lajot, L. Cornelissen, L. De Mot, S. Hanoteaux, Y. Dockx, B.E.L.S.A.R.I.N.E.Tresearch group, S. Denayer, Y. Lafort, I. Van Evercooren, M. Fonnesu, Y. Dupont, K. Blot, M. Vandromme, P. Mpakaniye, M.U. Paz   +15 more
core   +1 more source

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France

The Lancet Microbe
Summary: Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants. Nirsevimab, a long-acting monoclonal antibody targeting a conserved epitope on the prefusion F protein (site Φ), has shown high ...
ProfPhD Slim Fourati, Alawiya Reslan, PhD, Jérôme Bourret, PhD, Jean-Sébastien Casalegno, PhD, Yannis Rahou, Laurent Softic, PhD, Lionel Chollet, MD, Pauline Trémeaux, PhD, ProfPhD Berthe-Marie Imbert-Marcille, PhD, Sylvie Pillet, PhD, Nicolas Veyrenche, PhD, Agathe Boudet, PhD, Luc Deroche, MD, ProfPhD Sonia Burrel, MD, Lina Mouna, PharmD, Theophile Cocherie, MD, Aurélie Schnuriger, PhD, Charlotte Pronier, PhD, Lynda Handala, PharmD, Véronique Brodard, PhD, Floriane Gallais, PhD, Sylvie Larrat, PhD, Alexandre Regueme, PharmD, Nefert Candace Dossou, PharmD, Amandine Henry, PharmD, ProfPhD Elyanne Gault, PharmD, Cédric Hartard, PhD, Ségolène Brichler, PhD, Alice Moisan, PhD, ProfPhD Véronique Avettand-Fenoel, PhD, Caroline Lefeuvre, PharmD, Ilka Engelmann, PhD, ProfPhD Sandrine Castelain, PhD, Audrey Mirand, PhD, Maud Salmona, PhD, Marie-Christine Jaffar-Bandjee, PhD, Mohamed Ader, Sarah Seng, Pierre Cappy, PhD, ProfPhD Christophe Rodriguez, PhD, Arnaud Ly, Georges Dos Santos, PhD, ProfPhD Olivier Schwartz, PhD, Chloé Petiot, Delphine Planas, PhD, Samar Berreira Ibraim, PhD, Kévin Da Silva, PhD, Amélie Recoing, MD, ProfPhD Jean-Michel Pawlotsky, MD, Frédéric Lemoine, PhD, ProfPhD Etienne Audureau, PhD, ProfPhD Marie-Anne Rameix-Welti, PhD, Naël Zemali, Sonia Burrel, Pantxika Bellecave, Alice Moisan, Zakasoa-Mbololona Zavaoarisaina, Romain Legros, Boris Derman, Vincent Pargny, Hortense Petat, Jean-Christophe Plantier, Véronique Avettand-Fenoel, Salim Ferrani, Jérome Guinard, Clémence Guillaume, Gilbert Mchantaf, Victoria Marie, Laurent Bret, Fabien Lesne, Anthony de Oliveira, Alexandre Regueme, Kazali Alidjinou, Lionel Chollet, Vincent Gardan, Ségolène Brichler, Loic de Pontual, Camille Aupiais, Stéphane Marot, Aurélie Schnuriger, Marine Perrier, Pierre Jatteau, Djeneba Fofana, Théophile Cocherie, Elisa Teyssou, Cathia Soulié, Vincent Calvez, Sylvie Larrat, Anne Faisant, Guillaume Mortamet, Caroline Tournegros, Mohamed Habib, Sylvie Pillet, Aymeric Cantais, Franck Zekre, Thomas Bourlet, Oulfa Boussetta-Charfi, Sara Chenafi-Adham, Eva Gleizes, Cédric Hartard, Caroline Lefeuvre, Elise Bouthry, Lina Mouna, Fairly Warnakulasuriya, Quentin Le Hingrat, Marie-Christine Jaffar-Bandjee, Diana Heaugwane, Benjamin Azemar, Nicolas Mnemosyme, Laurent Souply, Catherine François, Sandrine Castelain, Cinthia Rames, Arnaud Bécourt, Ilka Engelmann, Eric Jeziorski, Vincent Foulongne, Lynda Handala, Catherine Gaudy-Graffin, Agathe Crémadés, Amandine Henry, Alessandra Pennisi, Maud Salmona, Jérôme Le Goff, Audrey Gabassi, Marie-Laure Néré, Marine Minier, Audrey Baron, Stéphane Bonacorsi, Naim Ouldali, Abdeljalil Senhaji Rachik, Marie-Anne Rameix-Welti, Alawyia Reslan, Yannis Rahou, Banujaa Jeyarajah, Anne Huard de Verneuil, Jérome Bourret, Frédéric Lemoine, Kévin Da Silva, Samar Berreira Ibraim, Vincent Enouf, Danielle Perez-Bercoff, Lucy Mosscrop, Etienne Simon-Loriere, Nefert Candace Dossou, Astrid Vabret, Slim Fourati, Christophe Rodriguez, Jean-Michel Pawlotsky, Pierre Cappy, Alexandre Soulier, Mohamed Ader, Sarah Seng, Arnaud Ly, Amandine Caillault, Pierre-André Natella, Etienne Audureau, Georges Dos Santos, Laurence Fagour, Anne-Julie Schapira, Olivier Flechelles, Luc Deroche, Nicolas Lévêque, Claire Morton Fauche, Sarah Borel, Erwan Ripley, Juliette Aubin, Berthe-Marie Imbert, Louise Castain, Audreay Rodallec, Justine Sourice, Christele Gras-Le Guen, Anne Chauvire-Drouard, Elyanne Gault, Frédérique Moreau, Claire Deback, Floriane Gallais, Morgane Solis, Valentin Stephan, Léa Pilorgé, Sophie Vallet, Léa Gaitan, Sylvie Rogez, Audrey Mirand, Cecile Henquell, Charlotte Pronier, Claire Grolhier, Vincent Thibault, Pauline Trémeaux, Isabelle Claudet, Mélanie Pucelle, Laetitia Staes, Camille Vellas, Sofia Demmou, Romain Carcenac, Nicolas Veyrenche, Jean-sébastien Casalegno, Alexandre Gaymard, Jose Kombou, Antonin Bal, Stanislas Ogoudjobi, Agathe Boudet, Amélie Recoing   +202 more
doaj   +1 more source

First Phylodynamic Analysis of HRSV‐A and HRSV‐B in Rio de Janeiro, Brazil, Reveals Recurrent Dispersals From the Megalopolis Center to Suburban Cities

Journal of Medical Virology, Volume 98, Issue 10, October 2026.
ABSTRACT Human respiratory syncytial virus (HRSV) is the leading cause of acute lower respiratory tract infections in infants and represents a major burden to public health systems worldwide. Despite its epidemiological relevance, genomic surveillance of HRSV in Brazil remains limited.
Alessandra Pavan Lamarca, Melise Chaves Silveira, Renata Campos Azevedo, Maria Angélica Arpon Marandino Guimarães, Claudia Maria Braga de Mello, Adriana Cardoso Camargo, Leandro Magalhães de Souza, Alexandra Lehmkuhl Gerber, Ana Paula C. Guimarães, Andréa Cony Cavalcanti, Ana Tereza Ribeiro Vasconcelos   +10 more
wiley   +1 more source

Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract disease, and the standard prevention strategy in Japan is limited to high-risk infants.
Shinichi Noto, Alexia Kieffer, Samira Soudani, Takeshi Arashiro, Chiho Tadera, Sebastien Eymere, Tobiasz Lemański, Xinyu Wang   +7 more
doaj   +1 more source

Vaccination in pediatric transplantation—General recommendations. A position paper by the European Reference Network TransplantChild

Journal of Pediatric Gastroenterology and Nutrition, Volume 83, Issue 4, Page 624-636, October 2026.
Abstract Infectious diseases remain a leading cause of morbidity and mortality among pediatric transplant recipients, despite significant advances in transplantation management. Vaccination is the most effective strategy to prevent infections; however, its efficacy is hindered in solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT)
Valeria Casotti, Francesco Saglio, Adriana Balduzzi, Peter Barany, Vibeke Brix Christensen, Simona Buelli, Daniele Donà, Maja Klaudel‐Dreszler, Sara Mosca, Andrea Pietrobattista, Michele Pinon, Giusy Ranucci, Lars Wennberg, Lorenzo D'Antiga, ERN TransplantChild Working Group, Claudia Vittori, Manuela Tumino, B. Ruben Brandsema, Lisa Swartling, Silvia Garazzino, Carlo Pace Napoleone, Kai Lehmberg, Isabella Guzzo, Charlotte Roy, Nicola Pradegan, Silvia Simo Nebot, Maria Herthelius, Angelo Mazza, Enrico Aidala, Oleg Godik, Victoria Bordon Cueto De Braem, Marco Busutti, Emily Claire Argento, Marc Garcia Lorenzo, Timo Jahnukainen, Zoryana Ivanyuk   +35 more
wiley   +1 more source

Impact of Nirsevimab immunoprophylaxis on professional exhaustion during two epidemics of respiratory syncytial virus [PDF]

Objective: We aimed to assess the impact of introducing immunoprophylaxis against respiratory syncytial virus in infants (healthy infants up to 6 months of age and vulnerable children up to 24 months) on the professional quality of life of pediatric ...
Castillo-Corullón, Silvia, Calderón Garrido, Caterina, Fullana-Tur, Maravillas, Iniesta-González, Sergio, Ferrando-Monleón, Susana, Ventura-Navarro, Ana, Arcos Machancoses, José Vicente, Barrés-Fernández, Ana   +7 more
core   +1 more source

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. [PDF]

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC\u27s Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants ...
Boom, Julie A, Toepfer, Ariana P, Goldstein, Leah, Clopper, Benjamin R, Dawood, Fatimah S, Englund, Janet A, Sahni, Leila C, Schlaudecker, Elizabeth P, New Vaccine Surveillance Network Product Effectiveness Collaborators, Albertin, Christina, Zerr, Danielle M, Schuster, Jennifer E, Michaels, Marian G, Betters, Kristina A, Rohlfs, Chelsea, Stewart, Laura S, Halasa, Natasha B, Selvarangan, Rangaraj, Piedra, Pedro A, McKeever, Erin R, McMorrow, Meredith L, Klein, Eileen J, Musa, Samar, Tannis, Ayzsa, Moline, Heidi L, Staat, Mary Allen, Williams, John V, Weinberg, Geoffrey A, Szilagyi, Peter G, Kalman, Casey, Banerjee, Dithi   +30 more
core   +3 more sources

Efectividad de la inmunización con nirsevimab en neonatos para prevenir hospitalizaciones por virus respiratorio sincitial durante dos temporadas en Navarra

Anales del Sistema Sanitario de Navarra
Fundamento. La infección por el virus respiratorio sincitial (VRS) es la principal causa de hospitalización en lactantes. En 2022 se autorizó el nirsevimab en la Unión Europea para prevenir la enfermedad respiratoria grave por VRS durante el primer año ...
Noelia Vera-Punzano, Ana Navascués, Leticia Armendáriz, Natividad Viguria, Mercedes Herranz-Aguirre, Manuel García Cenoz, Camino Trobajo-Sanmartín, Aitziber Echeverria, Iván Martínez-Baz, Carmen Ezpeleta, Guillermo Ezpeleta, Jesús Castilla   +11 more
doaj   +1 more source